243 related articles for article (PubMed ID: 22455883)
21. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
[TBL] [Abstract][Full Text] [Related]
22. Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta.
Rask K; Nilsson A; Brännström M; Carlsson P; Hellberg P; Janson PO; Hedin L; Sundfeldt K
Br J Cancer; 2003 Oct; 89(7):1298-304. PubMed ID: 14520463
[TBL] [Abstract][Full Text] [Related]
23. Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer.
Ahmed N; Riley C; Rice GE; Quinn MA; Baker MS
J Histochem Cytochem; 2002 Oct; 50(10):1371-80. PubMed ID: 12364570
[TBL] [Abstract][Full Text] [Related]
24. The role of activin A and Akt/GSK signaling in ovarian tumor biology.
Do TV; Kubba LA; Antenos M; Rademaker AW; Sturgis CD; Woodruff TK
Endocrinology; 2008 Aug; 149(8):3809-16. PubMed ID: 18450971
[TBL] [Abstract][Full Text] [Related]
25. [Expression and clinical significance of TLR9 in ovarian cancer].
Sha HL; Ouyang WX; Lü G
Zhonghua Zhong Liu Za Zhi; 2010 Dec; 32(12):913-6. PubMed ID: 21223799
[TBL] [Abstract][Full Text] [Related]
26. Neutral endopeptidase/CD10 expression in the stroma of epithelial ovarian carcinoma.
Khin EE; Kikkawa F; Ino K; Suzuki T; Shibata K; Kajiyama H; Tamakoshi K; Mizutani S
Int J Gynecol Pathol; 2003 Apr; 22(2):175-80. PubMed ID: 12649673
[TBL] [Abstract][Full Text] [Related]
27. u-PA expression in benign, borderline and malignant ovarian tumors.
Kiziridou AD; Toliou T; Stefanou D; Agnantis N
Anticancer Res; 2002; 22(2A):985-90. PubMed ID: 12014682
[TBL] [Abstract][Full Text] [Related]
28. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade.
Pan Y; Jiao J; Zhou C; Cheng Q; Hu Y; Chen H
Pathobiology; 2010; 77(6):283-8. PubMed ID: 21266826
[TBL] [Abstract][Full Text] [Related]
29. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
[TBL] [Abstract][Full Text] [Related]
30. BTG3 Overexpression Suppresses the Proliferation and Invasion in Epithelial Ovarian Cancer Cell by Regulating AKT/GSK3β/β-Catenin Signaling.
An Q; Zhou Y; Han C; Zhou Y; Li F; Li D
Reprod Sci; 2017 Oct; 24(10):1462-1468. PubMed ID: 28183228
[TBL] [Abstract][Full Text] [Related]
31. [Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor].
Zhang WY; Pan Y; Zhu LR; Zhang JZ; Zhang M; Feng K; Zhou L; Yu L; Zhang XM; Ng SW
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(42):2988-91. PubMed ID: 16324386
[TBL] [Abstract][Full Text] [Related]
32. [Expression and clinical significance of endostatin and vascular endothelial growth factor in ovarian carcinoma].
Shi HR; Song WJ; Chen ZM; Wu QH
Ai Zheng; 2005 Sep; 24(9):1127-31. PubMed ID: 16159439
[TBL] [Abstract][Full Text] [Related]
33. [Lymphatic metastasis and VEGF-C expression in ovarian epithelial tumors].
Ding MX; Li JC; Tang XH
Shi Yan Sheng Wu Xue Bao; 2003 Dec; 36(6):445-52. PubMed ID: 14724935
[TBL] [Abstract][Full Text] [Related]
34. Expression of c-myc and mutation of the KRAS gene in patients with ovarian mucinous tumors.
Li XS; Sun J; He XL
Genet Mol Res; 2015 Sep; 14(3):10752-9. PubMed ID: 26400304
[TBL] [Abstract][Full Text] [Related]
35. Silencing of CXCR4 blocks progression of ovarian cancer and depresses canonical Wnt signaling pathway.
Wang J; Cai J; Han F; Yang C; Tong Q; Cao T; Wu L; Wang Z
Int J Gynecol Cancer; 2011 Aug; 21(6):981-7. PubMed ID: 21738044
[TBL] [Abstract][Full Text] [Related]
36. [Human pituitary tumor transforming gene 1 expression in ovarian carcinoma and its clinical significance].
Cheng YX; Feng J; Zhang XY; Fu TY; Yao Y
Ai Zheng; 2004 Sep; 23(9):1026-30. PubMed ID: 15363195
[TBL] [Abstract][Full Text] [Related]
37. [Expression of EVEC in ovarian carcinoma and its biological significance].
Wang Q; Li XG; Zhang Y; Cao LQ; Deng ZH; Chen Y
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):676-80. PubMed ID: 21122382
[TBL] [Abstract][Full Text] [Related]
38. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract][Full Text] [Related]
39. [Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance].
Shao SL; Cai Y; Wang QH; Yan LJ; Zhao XY; Wang LX
Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):697-700. PubMed ID: 18246802
[TBL] [Abstract][Full Text] [Related]
40. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]